nodes	percent_of_prediction	percent_of_DWPC	metapath
Celecoxib—Etoricoxib—Vemurafenib—melanoma	0.529	1	CrCrCtD
Celecoxib—ORM1—Vemurafenib—melanoma	0.0727	0.489	CbGbCtD
Celecoxib—PTGS2—melanoma	0.0709	0.529	CbGaD
Celecoxib—ALB—melanoma	0.0631	0.471	CbGaD
Celecoxib—ALB—Vemurafenib—melanoma	0.0306	0.206	CbGbCtD
Celecoxib—CYP3A4—Temozolomide—melanoma	0.0175	0.118	CbGbCtD
Celecoxib—CYP2D6—Vemurafenib—melanoma	0.0151	0.101	CbGbCtD
Celecoxib—CYP3A4—Vemurafenib—melanoma	0.00959	0.0644	CbGbCtD
Celecoxib—CYP3A4—Docetaxel—melanoma	0.00329	0.0221	CbGbCtD
Celecoxib—CA6—ear—melanoma	0.00279	0.137	CbGeAlD
Celecoxib—CA6—hair follicle—melanoma	0.00147	0.0721	CbGeAlD
Celecoxib—MAPK14—hair follicle—melanoma	0.0013	0.0638	CbGeAlD
Celecoxib—MAPK14—blood vessel—melanoma	0.00122	0.0598	CbGeAlD
Celecoxib—PDPK1—retina—melanoma	0.0012	0.059	CbGeAlD
Celecoxib—MAPK14—neck—melanoma	0.000871	0.0428	CbGeAlD
Celecoxib—PTGS2—leg—melanoma	0.000821	0.0403	CbGeAlD
Celecoxib—PTGS2—hindlimb—melanoma	0.000733	0.036	CbGeAlD
Celecoxib—PDPK1—head—melanoma	0.000688	0.0338	CbGeAlD
Celecoxib—PTGS2—appendage—melanoma	0.000629	0.0309	CbGeAlD
Celecoxib—MAPK14—skin of body—melanoma	0.000564	0.0277	CbGeAlD
Celecoxib—PTGS2—skin epidermis—melanoma	0.000523	0.0257	CbGeAlD
Celecoxib—CA2—hair follicle—melanoma	0.000506	0.0248	CbGeAlD
Celecoxib—CA12—eye—melanoma	0.000492	0.0241	CbGeAlD
Celecoxib—PDPK1—lymph node—melanoma	0.000482	0.0237	CbGeAlD
Celecoxib—CA6—head—melanoma	0.000416	0.0204	CbGeAlD
Celecoxib—CA4—neck—melanoma	0.000409	0.0201	CbGeAlD
Celecoxib—PTGS2—endothelium—melanoma	0.00038	0.0186	CbGeAlD
Celecoxib—MAPK14—head—melanoma	0.000368	0.0181	CbGeAlD
Celecoxib—PTGS2—blood vessel—melanoma	0.00035	0.0172	CbGeAlD
Celecoxib—CA5B—mammalian vulva—melanoma	0.00035	0.0172	CbGeAlD
Celecoxib—CA2—neck—melanoma	0.000339	0.0167	CbGeAlD
Celecoxib—CA12—head—melanoma	0.000279	0.0137	CbGeAlD
Celecoxib—MAPK14—lymph node—melanoma	0.000258	0.0127	CbGeAlD
Celecoxib—CA2—eye—melanoma	0.000252	0.0124	CbGeAlD
Celecoxib—CA5B—head—melanoma	0.00025	0.0123	CbGeAlD
Celecoxib—CA2—retina—melanoma	0.00025	0.0123	CbGeAlD
Celecoxib—CA2—skin of body—melanoma	0.00022	0.0108	CbGeAlD
Celecoxib—CA2—mammalian vulva—melanoma	0.0002	0.00984	CbGeAlD
Celecoxib—ABCC4—head—melanoma	0.000188	0.00923	CbGeAlD
Celecoxib—CA5B—lymph node—melanoma	0.000175	0.00861	CbGeAlD
Celecoxib—CA4—head—melanoma	0.000173	0.00849	CbGeAlD
Celecoxib—PTGS2—skin of body—melanoma	0.000162	0.00796	CbGeAlD
Celecoxib—ORM1—lymph node—melanoma	0.000155	0.00762	CbGeAlD
Celecoxib—CA2—head—melanoma	0.000143	0.00704	CbGeAlD
Celecoxib—ALB—lymph node—melanoma	0.000136	0.00668	CbGeAlD
Celecoxib—ABCC4—lymph node—melanoma	0.000132	0.00646	CbGeAlD
Celecoxib—CA4—lymph node—melanoma	0.000121	0.00594	CbGeAlD
Celecoxib—Eye disorder—Carmustine—melanoma	0.000111	0.00168	CcSEcCtD
Celecoxib—Hyponatraemia—Docetaxel—melanoma	0.000111	0.00168	CcSEcCtD
Celecoxib—Gastrointestinal haemorrhage—Docetaxel—melanoma	0.00011	0.00167	CcSEcCtD
Celecoxib—Flushing—Carmustine—melanoma	0.00011	0.00167	CcSEcCtD
Celecoxib—Anaemia—Bleomycin—melanoma	0.000109	0.00166	CcSEcCtD
Celecoxib—Diarrhoea—Vemurafenib—melanoma	0.000109	0.00166	CcSEcCtD
Celecoxib—Migraine—Docetaxel—melanoma	0.000109	0.00165	CcSEcCtD
Celecoxib—Erythema multiforme—Temozolomide—melanoma	0.000109	0.00165	CcSEcCtD
Celecoxib—Eye disorder—Temozolomide—melanoma	0.000107	0.00163	CcSEcCtD
Celecoxib—Tinnitus—Temozolomide—melanoma	0.000107	0.00162	CcSEcCtD
Celecoxib—Flushing—Temozolomide—melanoma	0.000107	0.00162	CcSEcCtD
Celecoxib—Cardiac disorder—Temozolomide—melanoma	0.000107	0.00162	CcSEcCtD
Celecoxib—Arrhythmia—Carmustine—melanoma	0.000106	0.00161	CcSEcCtD
Celecoxib—Leukopenia—Bleomycin—melanoma	0.000106	0.00161	CcSEcCtD
Celecoxib—PTGS2—head—melanoma	0.000106	0.0052	CbGeAlD
Celecoxib—Dizziness—Vemurafenib—melanoma	0.000106	0.0016	CcSEcCtD
Celecoxib—Alopecia—Carmustine—melanoma	0.000105	0.00159	CcSEcCtD
Celecoxib—Angiopathy—Temozolomide—melanoma	0.000104	0.00158	CcSEcCtD
Celecoxib—Mental disorder—Carmustine—melanoma	0.000104	0.00158	CcSEcCtD
Celecoxib—Ataxia—Docetaxel—melanoma	0.000104	0.00157	CcSEcCtD
Celecoxib—Immune system disorder—Temozolomide—melanoma	0.000104	0.00157	CcSEcCtD
Celecoxib—Mediastinal disorder—Temozolomide—melanoma	0.000103	0.00157	CcSEcCtD
Celecoxib—Cough—Bleomycin—melanoma	0.000103	0.00157	CcSEcCtD
Celecoxib—Anaemia—Dactinomycin—melanoma	0.000102	0.00155	CcSEcCtD
Celecoxib—Liver function test abnormal—Docetaxel—melanoma	0.000102	0.00155	CcSEcCtD
Celecoxib—Vomiting—Vemurafenib—melanoma	0.000101	0.00154	CcSEcCtD
Celecoxib—Alopecia—Temozolomide—melanoma	0.000101	0.00154	CcSEcCtD
Celecoxib—Dry skin—Docetaxel—melanoma	0.000101	0.00153	CcSEcCtD
Celecoxib—Myalgia—Bleomycin—melanoma	0.000101	0.00153	CcSEcCtD
Celecoxib—Chest pain—Bleomycin—melanoma	0.000101	0.00153	CcSEcCtD
Celecoxib—Abdominal pain upper—Docetaxel—melanoma	0.000101	0.00153	CcSEcCtD
Celecoxib—Rash—Vemurafenib—melanoma	0.000101	0.00153	CcSEcCtD
Celecoxib—Mental disorder—Temozolomide—melanoma	0.000101	0.00153	CcSEcCtD
Celecoxib—Dermatitis—Vemurafenib—melanoma	0.000101	0.00153	CcSEcCtD
Celecoxib—CA2—lymph node—melanoma	0.0001	0.00493	CbGeAlD
Celecoxib—Back pain—Carmustine—melanoma	0.0001	0.00152	CcSEcCtD
Celecoxib—Headache—Vemurafenib—melanoma	0.0001	0.00152	CcSEcCtD
Celecoxib—Breast disorder—Docetaxel—melanoma	9.97e-05	0.00151	CcSEcCtD
Celecoxib—Toxic epidermal necrolysis—Docetaxel—melanoma	9.94e-05	0.00151	CcSEcCtD
Celecoxib—Aspartate aminotransferase increased—Docetaxel—melanoma	9.94e-05	0.00151	CcSEcCtD
Celecoxib—Leukopenia—Dactinomycin—melanoma	9.89e-05	0.0015	CcSEcCtD
Celecoxib—Nasopharyngitis—Docetaxel—melanoma	9.87e-05	0.0015	CcSEcCtD
Celecoxib—Dysgeusia—Temozolomide—melanoma	9.78e-05	0.00148	CcSEcCtD
Celecoxib—Confusional state—Bleomycin—melanoma	9.75e-05	0.00148	CcSEcCtD
Celecoxib—Vision blurred—Carmustine—melanoma	9.74e-05	0.00148	CcSEcCtD
Celecoxib—Alanine aminotransferase increased—Docetaxel—melanoma	9.73e-05	0.00148	CcSEcCtD
Celecoxib—Oedema—Bleomycin—melanoma	9.67e-05	0.00147	CcSEcCtD
Celecoxib—Anaphylactic shock—Bleomycin—melanoma	9.67e-05	0.00147	CcSEcCtD
Celecoxib—Back pain—Temozolomide—melanoma	9.66e-05	0.00147	CcSEcCtD
Celecoxib—Infection—Bleomycin—melanoma	9.6e-05	0.00146	CcSEcCtD
Celecoxib—Anaemia—Carmustine—melanoma	9.56e-05	0.00145	CcSEcCtD
Celecoxib—Dysphagia—Docetaxel—melanoma	9.54e-05	0.00145	CcSEcCtD
Celecoxib—Nausea—Vemurafenib—melanoma	9.48e-05	0.00144	CcSEcCtD
Celecoxib—Thrombocytopenia—Bleomycin—melanoma	9.46e-05	0.00144	CcSEcCtD
Celecoxib—Vision blurred—Temozolomide—melanoma	9.42e-05	0.00143	CcSEcCtD
Celecoxib—Myalgia—Dactinomycin—melanoma	9.4e-05	0.00143	CcSEcCtD
Celecoxib—Bronchospasm—Docetaxel—melanoma	9.38e-05	0.00142	CcSEcCtD
Celecoxib—Angina pectoris—Docetaxel—melanoma	9.29e-05	0.00141	CcSEcCtD
Celecoxib—Leukopenia—Carmustine—melanoma	9.25e-05	0.0014	CcSEcCtD
Celecoxib—Anaemia—Temozolomide—melanoma	9.23e-05	0.0014	CcSEcCtD
Celecoxib—Anorexia—Bleomycin—melanoma	9.21e-05	0.0014	CcSEcCtD
Celecoxib—Angioedema—Temozolomide—melanoma	9.13e-05	0.00139	CcSEcCtD
Celecoxib—CYP2D6—head—melanoma	9.09e-05	0.00447	CbGeAlD
Celecoxib—Pancytopenia—Docetaxel—melanoma	9.06e-05	0.00137	CcSEcCtD
Celecoxib—Oedema—Dactinomycin—melanoma	9.02e-05	0.00137	CcSEcCtD
Celecoxib—Vertigo—Temozolomide—melanoma	8.98e-05	0.00136	CcSEcCtD
Celecoxib—Infection—Dactinomycin—melanoma	8.96e-05	0.00136	CcSEcCtD
Celecoxib—Leukopenia—Temozolomide—melanoma	8.94e-05	0.00136	CcSEcCtD
Celecoxib—Hypertension—Carmustine—melanoma	8.93e-05	0.00135	CcSEcCtD
Celecoxib—Palpitations—Temozolomide—melanoma	8.83e-05	0.00134	CcSEcCtD
Celecoxib—Thrombocytopenia—Dactinomycin—melanoma	8.83e-05	0.00134	CcSEcCtD
Celecoxib—Musculoskeletal discomfort—Bleomycin—melanoma	8.81e-05	0.00134	CcSEcCtD
Celecoxib—Chest pain—Carmustine—melanoma	8.8e-05	0.00134	CcSEcCtD
Celecoxib—Myalgia—Carmustine—melanoma	8.8e-05	0.00134	CcSEcCtD
Celecoxib—Anxiety—Carmustine—melanoma	8.77e-05	0.00133	CcSEcCtD
Celecoxib—Cough—Temozolomide—melanoma	8.72e-05	0.00132	CcSEcCtD
Celecoxib—Paraesthesia—Bleomycin—melanoma	8.68e-05	0.00132	CcSEcCtD
Celecoxib—Weight increased—Docetaxel—melanoma	8.68e-05	0.00132	CcSEcCtD
Celecoxib—Hypertension—Temozolomide—melanoma	8.63e-05	0.00131	CcSEcCtD
Celecoxib—Dyspnoea—Bleomycin—melanoma	8.62e-05	0.00131	CcSEcCtD
Celecoxib—Anorexia—Dactinomycin—melanoma	8.59e-05	0.0013	CcSEcCtD
Celecoxib—Pneumonia—Docetaxel—melanoma	8.55e-05	0.0013	CcSEcCtD
Celecoxib—Confusional state—Carmustine—melanoma	8.51e-05	0.00129	CcSEcCtD
Celecoxib—Arthralgia—Temozolomide—melanoma	8.51e-05	0.00129	CcSEcCtD
Celecoxib—Myalgia—Temozolomide—melanoma	8.51e-05	0.00129	CcSEcCtD
Celecoxib—Infestation NOS—Docetaxel—melanoma	8.5e-05	0.00129	CcSEcCtD
Celecoxib—Infestation—Docetaxel—melanoma	8.5e-05	0.00129	CcSEcCtD
Celecoxib—Anxiety—Temozolomide—melanoma	8.48e-05	0.00129	CcSEcCtD
Celecoxib—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	8.45e-05	0.00128	CcSEcCtD
Celecoxib—Oedema—Carmustine—melanoma	8.44e-05	0.00128	CcSEcCtD
Celecoxib—Stevens-Johnson syndrome—Docetaxel—melanoma	8.43e-05	0.00128	CcSEcCtD
Celecoxib—Decreased appetite—Bleomycin—melanoma	8.4e-05	0.00128	CcSEcCtD
Celecoxib—Infection—Carmustine—melanoma	8.38e-05	0.00127	CcSEcCtD
Celecoxib—Acute coronary syndrome—Docetaxel—melanoma	8.38e-05	0.00127	CcSEcCtD
Celecoxib—Myocardial infarction—Docetaxel—melanoma	8.33e-05	0.00126	CcSEcCtD
Celecoxib—Neuropathy peripheral—Docetaxel—melanoma	8.33e-05	0.00126	CcSEcCtD
Celecoxib—Dry mouth—Temozolomide—melanoma	8.32e-05	0.00126	CcSEcCtD
Celecoxib—Stomatitis—Docetaxel—melanoma	8.29e-05	0.00126	CcSEcCtD
Celecoxib—Jaundice—Docetaxel—melanoma	8.29e-05	0.00126	CcSEcCtD
Celecoxib—Conjunctivitis—Docetaxel—melanoma	8.26e-05	0.00125	CcSEcCtD
Celecoxib—Thrombocytopenia—Carmustine—melanoma	8.26e-05	0.00125	CcSEcCtD
Celecoxib—Tachycardia—Carmustine—melanoma	8.24e-05	0.00125	CcSEcCtD
Celecoxib—Confusional state—Temozolomide—melanoma	8.22e-05	0.00125	CcSEcCtD
Celecoxib—Musculoskeletal discomfort—Dactinomycin—melanoma	8.21e-05	0.00125	CcSEcCtD
Celecoxib—Anaphylactic shock—Temozolomide—melanoma	8.15e-05	0.00124	CcSEcCtD
Celecoxib—Oedema—Temozolomide—melanoma	8.15e-05	0.00124	CcSEcCtD
Celecoxib—Infection—Temozolomide—melanoma	8.1e-05	0.00123	CcSEcCtD
Celecoxib—Anorexia—Carmustine—melanoma	8.04e-05	0.00122	CcSEcCtD
Celecoxib—Hepatobiliary disease—Docetaxel—melanoma	8.04e-05	0.00122	CcSEcCtD
Celecoxib—Epistaxis—Docetaxel—melanoma	8.02e-05	0.00122	CcSEcCtD
Celecoxib—Nervous system disorder—Temozolomide—melanoma	8e-05	0.00121	CcSEcCtD
Celecoxib—Thrombocytopenia—Temozolomide—melanoma	7.98e-05	0.00121	CcSEcCtD
Celecoxib—Feeling abnormal—Bleomycin—melanoma	7.97e-05	0.00121	CcSEcCtD
Celecoxib—Agranulocytosis—Docetaxel—melanoma	7.93e-05	0.0012	CcSEcCtD
Celecoxib—Skin disorder—Temozolomide—melanoma	7.92e-05	0.0012	CcSEcCtD
Celecoxib—Hyperhidrosis—Temozolomide—melanoma	7.88e-05	0.0012	CcSEcCtD
Celecoxib—Decreased appetite—Dactinomycin—melanoma	7.84e-05	0.00119	CcSEcCtD
Celecoxib—Fatigue—Dactinomycin—melanoma	7.77e-05	0.00118	CcSEcCtD
Celecoxib—Anorexia—Temozolomide—melanoma	7.77e-05	0.00118	CcSEcCtD
Celecoxib—Musculoskeletal discomfort—Carmustine—melanoma	7.69e-05	0.00117	CcSEcCtD
Celecoxib—Urticaria—Bleomycin—melanoma	7.68e-05	0.00117	CcSEcCtD
Celecoxib—Haemoglobin—Docetaxel—melanoma	7.67e-05	0.00116	CcSEcCtD
Celecoxib—Rhinitis—Docetaxel—melanoma	7.65e-05	0.00116	CcSEcCtD
Celecoxib—Body temperature increased—Bleomycin—melanoma	7.64e-05	0.00116	CcSEcCtD
Celecoxib—Haemorrhage—Docetaxel—melanoma	7.63e-05	0.00116	CcSEcCtD
Celecoxib—Hepatitis—Docetaxel—melanoma	7.63e-05	0.00116	CcSEcCtD
Celecoxib—Insomnia—Carmustine—melanoma	7.63e-05	0.00116	CcSEcCtD
Celecoxib—Hypoaesthesia—Docetaxel—melanoma	7.59e-05	0.00115	CcSEcCtD
Celecoxib—Paraesthesia—Carmustine—melanoma	7.58e-05	0.00115	CcSEcCtD
Celecoxib—Pharyngitis—Docetaxel—melanoma	7.58e-05	0.00115	CcSEcCtD
Celecoxib—Urinary tract disorder—Docetaxel—melanoma	7.54e-05	0.00114	CcSEcCtD
Celecoxib—Dyspnoea—Carmustine—melanoma	7.52e-05	0.00114	CcSEcCtD
Celecoxib—Oedema peripheral—Docetaxel—melanoma	7.52e-05	0.00114	CcSEcCtD
Celecoxib—Somnolence—Carmustine—melanoma	7.5e-05	0.00114	CcSEcCtD
Celecoxib—Connective tissue disorder—Docetaxel—melanoma	7.5e-05	0.00114	CcSEcCtD
Celecoxib—Urethral disorder—Docetaxel—melanoma	7.48e-05	0.00114	CcSEcCtD
Celecoxib—Feeling abnormal—Dactinomycin—melanoma	7.43e-05	0.00113	CcSEcCtD
Celecoxib—Musculoskeletal discomfort—Temozolomide—melanoma	7.43e-05	0.00113	CcSEcCtD
Celecoxib—PTGS2—lymph node—melanoma	7.41e-05	0.00364	CbGeAlD
Celecoxib—Insomnia—Temozolomide—melanoma	7.38e-05	0.00112	CcSEcCtD
Celecoxib—Gastrointestinal pain—Dactinomycin—melanoma	7.37e-05	0.00112	CcSEcCtD
Celecoxib—Decreased appetite—Carmustine—melanoma	7.34e-05	0.00111	CcSEcCtD
Celecoxib—Paraesthesia—Temozolomide—melanoma	7.32e-05	0.00111	CcSEcCtD
Celecoxib—Gastrointestinal disorder—Carmustine—melanoma	7.28e-05	0.00111	CcSEcCtD
Celecoxib—Dyspnoea—Temozolomide—melanoma	7.27e-05	0.0011	CcSEcCtD
Celecoxib—Somnolence—Temozolomide—melanoma	7.25e-05	0.0011	CcSEcCtD
Celecoxib—Erythema multiforme—Docetaxel—melanoma	7.22e-05	0.0011	CcSEcCtD
Celecoxib—Constipation—Carmustine—melanoma	7.22e-05	0.00109	CcSEcCtD
Celecoxib—Dyspepsia—Temozolomide—melanoma	7.18e-05	0.00109	CcSEcCtD
Celecoxib—Eye disorder—Docetaxel—melanoma	7.13e-05	0.00108	CcSEcCtD
Celecoxib—Abdominal pain—Dactinomycin—melanoma	7.13e-05	0.00108	CcSEcCtD
Celecoxib—Body temperature increased—Dactinomycin—melanoma	7.13e-05	0.00108	CcSEcCtD
Celecoxib—Hypersensitivity—Bleomycin—melanoma	7.12e-05	0.00108	CcSEcCtD
Celecoxib—Decreased appetite—Temozolomide—melanoma	7.09e-05	0.00108	CcSEcCtD
Celecoxib—Cardiac disorder—Docetaxel—melanoma	7.08e-05	0.00107	CcSEcCtD
Celecoxib—Flushing—Docetaxel—melanoma	7.08e-05	0.00107	CcSEcCtD
Celecoxib—Gastrointestinal disorder—Temozolomide—melanoma	7.04e-05	0.00107	CcSEcCtD
Celecoxib—Fatigue—Temozolomide—melanoma	7.03e-05	0.00107	CcSEcCtD
Celecoxib—Constipation—Temozolomide—melanoma	6.97e-05	0.00106	CcSEcCtD
Celecoxib—Feeling abnormal—Carmustine—melanoma	6.95e-05	0.00106	CcSEcCtD
Celecoxib—Asthenia—Bleomycin—melanoma	6.94e-05	0.00105	CcSEcCtD
Celecoxib—Angiopathy—Docetaxel—melanoma	6.93e-05	0.00105	CcSEcCtD
Celecoxib—Gastrointestinal pain—Carmustine—melanoma	6.9e-05	0.00105	CcSEcCtD
Celecoxib—Immune system disorder—Docetaxel—melanoma	6.89e-05	0.00105	CcSEcCtD
Celecoxib—Mediastinal disorder—Docetaxel—melanoma	6.88e-05	0.00104	CcSEcCtD
Celecoxib—Pruritus—Bleomycin—melanoma	6.84e-05	0.00104	CcSEcCtD
Celecoxib—Arrhythmia—Docetaxel—melanoma	6.82e-05	0.00103	CcSEcCtD
Celecoxib—Alopecia—Docetaxel—melanoma	6.74e-05	0.00102	CcSEcCtD
Celecoxib—Feeling abnormal—Temozolomide—melanoma	6.72e-05	0.00102	CcSEcCtD
Celecoxib—Mental disorder—Docetaxel—melanoma	6.69e-05	0.00101	CcSEcCtD
Celecoxib—Body temperature increased—Carmustine—melanoma	6.67e-05	0.00101	CcSEcCtD
Celecoxib—Abdominal pain—Carmustine—melanoma	6.67e-05	0.00101	CcSEcCtD
Celecoxib—Gastrointestinal pain—Temozolomide—melanoma	6.67e-05	0.00101	CcSEcCtD
Celecoxib—Hypersensitivity—Dactinomycin—melanoma	6.64e-05	0.00101	CcSEcCtD
Celecoxib—Dysgeusia—Docetaxel—melanoma	6.51e-05	0.000987	CcSEcCtD
Celecoxib—Urticaria—Temozolomide—melanoma	6.48e-05	0.000983	CcSEcCtD
Celecoxib—Asthenia—Dactinomycin—melanoma	6.47e-05	0.000981	CcSEcCtD
Celecoxib—Body temperature increased—Temozolomide—melanoma	6.45e-05	0.000978	CcSEcCtD
Celecoxib—Abdominal pain—Temozolomide—melanoma	6.45e-05	0.000978	CcSEcCtD
Celecoxib—Back pain—Docetaxel—melanoma	6.43e-05	0.000975	CcSEcCtD
Celecoxib—Etoricoxib—PTGS2—melanoma	6.4e-05	1	CrCbGaD
Celecoxib—Muscle spasms—Docetaxel—melanoma	6.39e-05	0.000969	CcSEcCtD
Celecoxib—Hypersensitivity—Carmustine—melanoma	6.22e-05	0.000943	CcSEcCtD
Celecoxib—Diarrhoea—Dactinomycin—melanoma	6.17e-05	0.000936	CcSEcCtD
Celecoxib—Vomiting—Bleomycin—melanoma	6.15e-05	0.000933	CcSEcCtD
Celecoxib—Anaemia—Docetaxel—melanoma	6.14e-05	0.000932	CcSEcCtD
Celecoxib—Rash—Bleomycin—melanoma	6.1e-05	0.000925	CcSEcCtD
Celecoxib—Dermatitis—Bleomycin—melanoma	6.09e-05	0.000924	CcSEcCtD
Celecoxib—Asthenia—Carmustine—melanoma	6.05e-05	0.000919	CcSEcCtD
Celecoxib—Hypersensitivity—Temozolomide—melanoma	6.01e-05	0.000912	CcSEcCtD
Celecoxib—Syncope—Docetaxel—melanoma	5.96e-05	0.000904	CcSEcCtD
Celecoxib—Leukopenia—Docetaxel—melanoma	5.95e-05	0.000902	CcSEcCtD
Celecoxib—Palpitations—Docetaxel—melanoma	5.87e-05	0.000891	CcSEcCtD
Celecoxib—Asthenia—Temozolomide—melanoma	5.85e-05	0.000888	CcSEcCtD
Celecoxib—Loss of consciousness—Docetaxel—melanoma	5.84e-05	0.000886	CcSEcCtD
Celecoxib—Cough—Docetaxel—melanoma	5.8e-05	0.00088	CcSEcCtD
Celecoxib—Diarrhoea—Carmustine—melanoma	5.77e-05	0.000876	CcSEcCtD
Celecoxib—Pruritus—Temozolomide—melanoma	5.77e-05	0.000875	CcSEcCtD
Celecoxib—Nausea—Bleomycin—melanoma	5.74e-05	0.000871	CcSEcCtD
Celecoxib—Hypertension—Docetaxel—melanoma	5.74e-05	0.00087	CcSEcCtD
Celecoxib—Vomiting—Dactinomycin—melanoma	5.73e-05	0.00087	CcSEcCtD
Celecoxib—Rash—Dactinomycin—melanoma	5.68e-05	0.000863	CcSEcCtD
Celecoxib—Chest pain—Docetaxel—melanoma	5.66e-05	0.000858	CcSEcCtD
Celecoxib—Myalgia—Docetaxel—melanoma	5.66e-05	0.000858	CcSEcCtD
Celecoxib—Arthralgia—Docetaxel—melanoma	5.66e-05	0.000858	CcSEcCtD
Celecoxib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	5.62e-05	0.000852	CcSEcCtD
Celecoxib—Dizziness—Carmustine—melanoma	5.58e-05	0.000847	CcSEcCtD
Celecoxib—Diarrhoea—Temozolomide—melanoma	5.58e-05	0.000847	CcSEcCtD
Celecoxib—Dry mouth—Docetaxel—melanoma	5.53e-05	0.000839	CcSEcCtD
Celecoxib—Confusional state—Docetaxel—melanoma	5.47e-05	0.00083	CcSEcCtD
Celecoxib—Anaphylactic shock—Docetaxel—melanoma	5.42e-05	0.000823	CcSEcCtD
Celecoxib—Oedema—Docetaxel—melanoma	5.42e-05	0.000823	CcSEcCtD
Celecoxib—Dizziness—Temozolomide—melanoma	5.39e-05	0.000818	CcSEcCtD
Celecoxib—Infection—Docetaxel—melanoma	5.39e-05	0.000817	CcSEcCtD
Celecoxib—Vomiting—Carmustine—melanoma	5.37e-05	0.000814	CcSEcCtD
Celecoxib—Nausea—Dactinomycin—melanoma	5.36e-05	0.000813	CcSEcCtD
Celecoxib—Shock—Docetaxel—melanoma	5.34e-05	0.00081	CcSEcCtD
Celecoxib—Rash—Carmustine—melanoma	5.32e-05	0.000807	CcSEcCtD
Celecoxib—Nervous system disorder—Docetaxel—melanoma	5.32e-05	0.000807	CcSEcCtD
Celecoxib—Dermatitis—Carmustine—melanoma	5.32e-05	0.000807	CcSEcCtD
Celecoxib—Thrombocytopenia—Docetaxel—melanoma	5.31e-05	0.000806	CcSEcCtD
Celecoxib—Tachycardia—Docetaxel—melanoma	5.29e-05	0.000803	CcSEcCtD
Celecoxib—Headache—Carmustine—melanoma	5.29e-05	0.000802	CcSEcCtD
Celecoxib—Skin disorder—Docetaxel—melanoma	5.27e-05	0.000799	CcSEcCtD
Celecoxib—Vomiting—Temozolomide—melanoma	5.18e-05	0.000787	CcSEcCtD
Celecoxib—Anorexia—Docetaxel—melanoma	5.17e-05	0.000784	CcSEcCtD
Celecoxib—Rash—Temozolomide—melanoma	5.14e-05	0.00078	CcSEcCtD
Celecoxib—Dermatitis—Temozolomide—melanoma	5.14e-05	0.000779	CcSEcCtD
Celecoxib—Headache—Temozolomide—melanoma	5.11e-05	0.000775	CcSEcCtD
Celecoxib—Nausea—Carmustine—melanoma	5.01e-05	0.000761	CcSEcCtD
Celecoxib—Musculoskeletal discomfort—Docetaxel—melanoma	4.94e-05	0.00075	CcSEcCtD
Celecoxib—Insomnia—Docetaxel—melanoma	4.9e-05	0.000744	CcSEcCtD
Celecoxib—Paraesthesia—Docetaxel—melanoma	4.87e-05	0.000739	CcSEcCtD
Celecoxib—Nausea—Temozolomide—melanoma	4.84e-05	0.000735	CcSEcCtD
Celecoxib—Dyspnoea—Docetaxel—melanoma	4.83e-05	0.000734	CcSEcCtD
Celecoxib—Somnolence—Docetaxel—melanoma	4.82e-05	0.000731	CcSEcCtD
Celecoxib—Dyspepsia—Docetaxel—melanoma	4.77e-05	0.000724	CcSEcCtD
Celecoxib—Decreased appetite—Docetaxel—melanoma	4.71e-05	0.000715	CcSEcCtD
Celecoxib—Gastrointestinal disorder—Docetaxel—melanoma	4.68e-05	0.00071	CcSEcCtD
Celecoxib—Fatigue—Docetaxel—melanoma	4.68e-05	0.000709	CcSEcCtD
Celecoxib—Constipation—Docetaxel—melanoma	4.64e-05	0.000704	CcSEcCtD
Celecoxib—Feeling abnormal—Docetaxel—melanoma	4.47e-05	0.000678	CcSEcCtD
Celecoxib—Gastrointestinal pain—Docetaxel—melanoma	4.43e-05	0.000673	CcSEcCtD
Celecoxib—Abdominal pain—Docetaxel—melanoma	4.29e-05	0.00065	CcSEcCtD
Celecoxib—Body temperature increased—Docetaxel—melanoma	4.29e-05	0.00065	CcSEcCtD
Celecoxib—Hypersensitivity—Docetaxel—melanoma	4e-05	0.000606	CcSEcCtD
Celecoxib—Asthenia—Docetaxel—melanoma	3.89e-05	0.00059	CcSEcCtD
Celecoxib—Pruritus—Docetaxel—melanoma	3.84e-05	0.000582	CcSEcCtD
Celecoxib—Diarrhoea—Docetaxel—melanoma	3.71e-05	0.000563	CcSEcCtD
Celecoxib—Dizziness—Docetaxel—melanoma	3.59e-05	0.000544	CcSEcCtD
Celecoxib—Vomiting—Docetaxel—melanoma	3.45e-05	0.000523	CcSEcCtD
Celecoxib—Rash—Docetaxel—melanoma	3.42e-05	0.000519	CcSEcCtD
Celecoxib—Dermatitis—Docetaxel—melanoma	3.42e-05	0.000518	CcSEcCtD
Celecoxib—Headache—Docetaxel—melanoma	3.4e-05	0.000515	CcSEcCtD
Celecoxib—Nausea—Docetaxel—melanoma	3.22e-05	0.000489	CcSEcCtD
Celecoxib—PDPK1—Disease—HRAS—melanoma	1.97e-06	1.94e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—TERT—melanoma	1.97e-06	1.94e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—PIK3CB—melanoma	1.97e-06	1.94e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—RAC1—melanoma	1.97e-06	1.94e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—CD4—melanoma	1.97e-06	1.93e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—PDGFRA—melanoma	1.96e-06	1.92e-05	CbGpPWpGaD
Celecoxib—CA12—Metabolism—AKT1—melanoma	1.95e-06	1.92e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—GNA11—melanoma	1.94e-06	1.91e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—PIK3CB—melanoma	1.94e-06	1.91e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—PRKCA—melanoma	1.94e-06	1.91e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—ERCC2—melanoma	1.92e-06	1.89e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—PHGDH—melanoma	1.91e-06	1.88e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—LUM—melanoma	1.91e-06	1.88e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—VEGFA—melanoma	1.91e-06	1.88e-05	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—HRAS—melanoma	1.91e-06	1.88e-05	CbGpPWpGaD
Celecoxib—MAPK14—Developmental Biology—AKT1—melanoma	1.91e-06	1.88e-05	CbGpPWpGaD
Celecoxib—CA4—Metabolism—PIK3CA—melanoma	1.91e-06	1.87e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—FASN—melanoma	1.9e-06	1.87e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—STAT3—melanoma	1.89e-06	1.86e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—MAP2K2—melanoma	1.89e-06	1.86e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—NRAS—melanoma	1.89e-06	1.86e-05	CbGpPWpGaD
Celecoxib—PDPK1—Disease—IL6—melanoma	1.89e-06	1.86e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—melanoma	1.89e-06	1.86e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism of lipids and lipoproteins—PTEN—melanoma	1.89e-06	1.86e-05	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—AKT1—melanoma	1.89e-06	1.86e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—HIF1A—melanoma	1.89e-06	1.86e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—HPSE—melanoma	1.88e-06	1.85e-05	CbGpPWpGaD
Celecoxib—ALB—Platelet activation, signaling and aggregation—AKT1—melanoma	1.88e-06	1.85e-05	CbGpPWpGaD
Celecoxib—MAPK14—Hemostasis—AKT1—melanoma	1.87e-06	1.84e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—SLC5A5—melanoma	1.87e-06	1.84e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—CDKN1B—melanoma	1.85e-06	1.82e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—CUBN—melanoma	1.84e-06	1.81e-05	CbGpPWpGaD
Celecoxib—CA2—Metabolism—PIK3CA—melanoma	1.83e-06	1.8e-05	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—IL6—melanoma	1.83e-06	1.8e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—melanoma	1.82e-06	1.79e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—MAPK3—melanoma	1.81e-06	1.78e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—IL2—melanoma	1.81e-06	1.78e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—GNAQ—melanoma	1.81e-06	1.78e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—CD44—melanoma	1.81e-06	1.78e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—KDR—melanoma	1.8e-06	1.78e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—TERT—melanoma	1.8e-06	1.77e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—HLA-A—melanoma	1.8e-06	1.77e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—RAC1—melanoma	1.8e-06	1.77e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—IL2—melanoma	1.78e-06	1.75e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—BSG—melanoma	1.78e-06	1.75e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—SDHD—melanoma	1.78e-06	1.75e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—CSPG4—melanoma	1.78e-06	1.75e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	1.77e-06	1.74e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—ABCB1—melanoma	1.76e-06	1.73e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—MYC—melanoma	1.76e-06	1.73e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism of lipids and lipoproteins—PTGS2—melanoma	1.75e-06	1.72e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—CTNNB1—melanoma	1.75e-06	1.72e-05	CbGpPWpGaD
Celecoxib—PDPK1—Disease—AKT1—melanoma	1.74e-06	1.72e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—FN1—melanoma	1.74e-06	1.71e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—CYP1B1—melanoma	1.73e-06	1.7e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—GPAM—melanoma	1.72e-06	1.7e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—MAPK1—melanoma	1.72e-06	1.69e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—EGFR—melanoma	1.72e-06	1.69e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—HIF1A—melanoma	1.72e-06	1.69e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—CDKN1A—melanoma	1.71e-06	1.68e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—PTEN—melanoma	1.7e-06	1.68e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—NOTCH1—melanoma	1.7e-06	1.67e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—CYP17A1—melanoma	1.7e-06	1.67e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—NFKB1—melanoma	1.69e-06	1.67e-05	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—AKT1—melanoma	1.68e-06	1.66e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—CYP17A1—melanoma	1.68e-06	1.66e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—CD80—melanoma	1.67e-06	1.64e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—APC—melanoma	1.66e-06	1.64e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—KIT—melanoma	1.66e-06	1.64e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—PIK3CG—melanoma	1.66e-06	1.64e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—melanoma	1.66e-06	1.63e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—EGF—melanoma	1.64e-06	1.62e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism of lipids and lipoproteins—ALB—melanoma	1.64e-06	1.61e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—KRAS—melanoma	1.63e-06	1.6e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—PRKCA—melanoma	1.62e-06	1.6e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—ERCC2—melanoma	1.61e-06	1.58e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—GNA11—melanoma	1.6e-06	1.58e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—GNA11—melanoma	1.59e-06	1.56e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—FASN—melanoma	1.57e-06	1.54e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—NOS2—melanoma	1.57e-06	1.54e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—BRAF—melanoma	1.56e-06	1.54e-05	CbGpPWpGaD
Celecoxib—CA4—Metabolism—AKT1—melanoma	1.56e-06	1.53e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—FASN—melanoma	1.56e-06	1.53e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—NOTCH1—melanoma	1.55e-06	1.53e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—SLC5A5—melanoma	1.54e-06	1.52e-05	CbGpPWpGaD
Celecoxib—CA9—Metabolism—PIK3CA—melanoma	1.54e-06	1.51e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—SLC5A5—melanoma	1.53e-06	1.51e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism of lipids and lipoproteins—PTEN—melanoma	1.53e-06	1.5e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—STAT3—melanoma	1.52e-06	1.5e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—IGF1—melanoma	1.52e-06	1.5e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—CD80—melanoma	1.52e-06	1.49e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—NRAS—melanoma	1.52e-06	1.49e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—APC—melanoma	1.52e-06	1.49e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—KIT—melanoma	1.52e-06	1.49e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—VEGFA—melanoma	1.52e-06	1.49e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—EGF—melanoma	1.5e-06	1.47e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—NRAS—melanoma	1.5e-06	1.47e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—PIK3CA—melanoma	1.49e-06	1.47e-05	CbGpPWpGaD
Celecoxib—CA2—Metabolism—AKT1—melanoma	1.49e-06	1.47e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—GNAQ—melanoma	1.49e-06	1.47e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—CD44—melanoma	1.49e-06	1.47e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—GNAQ—melanoma	1.48e-06	1.45e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—CD44—melanoma	1.48e-06	1.45e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—MAP2K1—melanoma	1.47e-06	1.45e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—PLA2G6—melanoma	1.47e-06	1.44e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—PIK3CD—melanoma	1.46e-06	1.44e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—MAPK3—melanoma	1.45e-06	1.43e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	1.45e-06	1.42e-05	CbGpPWpGaD
Celecoxib—MAPK14—Gene Expression—MAPK3—melanoma	1.45e-06	1.42e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—TP53—melanoma	1.45e-06	1.42e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—melanoma	1.43e-06	1.41e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—MAPK3—melanoma	1.43e-06	1.41e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—CYP1B1—melanoma	1.43e-06	1.41e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—BRAF—melanoma	1.43e-06	1.4e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—ABCB1—melanoma	1.43e-06	1.4e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—CYP1B1—melanoma	1.42e-06	1.39e-05	CbGpPWpGaD
Celecoxib—MAPK14—Gene Expression—MYC—melanoma	1.41e-06	1.38e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—FGF2—melanoma	1.4e-06	1.38e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—MAPK1—melanoma	1.38e-06	1.36e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—EGFR—melanoma	1.38e-06	1.36e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—HRAS—melanoma	1.38e-06	1.36e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—MAPK1—melanoma	1.36e-06	1.34e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—MAP2K1—melanoma	1.34e-06	1.32e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—PIK3CD—melanoma	1.33e-06	1.31e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	1.33e-06	1.31e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—IL6—melanoma	1.32e-06	1.3e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—VCAN—melanoma	1.32e-06	1.29e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—PRKCA—melanoma	1.31e-06	1.29e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—MDM2—melanoma	1.31e-06	1.29e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—KRAS—melanoma	1.31e-06	1.29e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—ERCC2—melanoma	1.3e-06	1.28e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—ERBB2—melanoma	1.29e-06	1.27e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—KRAS—melanoma	1.29e-06	1.27e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—FGF2—melanoma	1.28e-06	1.26e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—PIK3CB—melanoma	1.27e-06	1.25e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—PIK3CG—melanoma	1.27e-06	1.25e-05	CbGpPWpGaD
Celecoxib—CA9—Metabolism—AKT1—melanoma	1.26e-06	1.24e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—melanoma	1.25e-06	1.23e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—PPARG—melanoma	1.23e-06	1.21e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—CXCL8—melanoma	1.22e-06	1.2e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—AKT1—melanoma	1.22e-06	1.2e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—PIK3CA—melanoma	1.2e-06	1.18e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—CDKN1B—melanoma	1.2e-06	1.18e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—MDM2—melanoma	1.19e-06	1.18e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—PIK3CA—melanoma	1.18e-06	1.16e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—ERBB2—melanoma	1.18e-06	1.16e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—ABCB1—melanoma	1.18e-06	1.16e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—CASP3—melanoma	1.17e-06	1.15e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—IL2—melanoma	1.17e-06	1.15e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—ABCB1—melanoma	1.17e-06	1.15e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—PIK3CB—melanoma	1.16e-06	1.14e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—CD4—melanoma	1.16e-06	1.14e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—TP53—melanoma	1.15e-06	1.13e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—CCND1—melanoma	1.14e-06	1.12e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—CTNNB1—melanoma	1.13e-06	1.11e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—PIK3CD—melanoma	1.12e-06	1.1e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—HRAS—melanoma	1.11e-06	1.09e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—CYP17A1—melanoma	1.11e-06	1.09e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—MMP9—melanoma	1.11e-06	1.09e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—CDKN1A—melanoma	1.1e-06	1.09e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—ALB—melanoma	1.1e-06	1.08e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—PTEN—melanoma	1.1e-06	1.08e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—NFKB1—melanoma	1.1e-06	1.08e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—HRAS—melanoma	1.1e-06	1.08e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—CDKN1B—melanoma	1.09e-06	1.07e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—PRKCA—melanoma	1.08e-06	1.07e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	1.08e-06	1.06e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—ERCC2—melanoma	1.07e-06	1.06e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—PRKCA—melanoma	1.07e-06	1.06e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—ERCC2—melanoma	1.07e-06	1.05e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—IL6—melanoma	1.06e-06	1.05e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—GNA11—melanoma	1.05e-06	1.03e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—CTNNB1—melanoma	1.03e-06	1.01e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—PIK3CG—melanoma	1.03e-06	1.01e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—FASN—melanoma	1.03e-06	1.01e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—SLC5A5—melanoma	1.01e-06	9.93e-06	CbGpPWpGaD
Celecoxib—PTGS2—Disease—CDKN1A—melanoma	1.01e-06	9.9e-06	CbGpPWpGaD
Celecoxib—PTGS2—Disease—PTEN—melanoma	1e-06	9.88e-06	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—VEGFA—melanoma	9.94e-07	9.78e-06	CbGpPWpGaD
Celecoxib—ALB—Metabolism—PPARG—melanoma	9.92e-07	9.76e-06	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—STAT3—melanoma	9.85e-07	9.69e-06	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—NRAS—melanoma	9.82e-07	9.66e-06	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—AKT1—melanoma	9.81e-07	9.65e-06	CbGpPWpGaD
Celecoxib—MAPK14—Gene Expression—AKT1—melanoma	9.76e-07	9.6e-06	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—GNAQ—melanoma	9.75e-07	9.59e-06	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—CD44—melanoma	9.75e-07	9.59e-06	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—PIK3CB—melanoma	9.73e-07	9.58e-06	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—AKT1—melanoma	9.67e-07	9.52e-06	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—MAPK3—melanoma	9.41e-07	9.25e-06	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—CYP1B1—melanoma	9.35e-07	9.19e-06	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—MYC—melanoma	9.15e-07	9e-06	CbGpPWpGaD
Celecoxib—ALB—Metabolism—PIK3CD—melanoma	9.03e-07	8.89e-06	CbGpPWpGaD
Celecoxib—PTGS2—Disease—STAT3—melanoma	8.98e-07	8.84e-06	CbGpPWpGaD
Celecoxib—PTGS2—Disease—NRAS—melanoma	8.96e-07	8.81e-06	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—MAPK1—melanoma	8.95e-07	8.8e-06	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—EGFR—melanoma	8.95e-07	8.8e-06	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	8.82e-07	8.68e-06	CbGpPWpGaD
Celecoxib—PTGS2—Disease—MAPK3—melanoma	8.58e-07	8.44e-06	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—PIK3CG—melanoma	8.49e-07	8.35e-06	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—KRAS—melanoma	8.45e-07	8.32e-06	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—PIK3CG—melanoma	8.41e-07	8.28e-06	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—PTEN—melanoma	8.41e-07	8.27e-06	CbGpPWpGaD
Celecoxib—PTGS2—Disease—MYC—melanoma	8.35e-07	8.21e-06	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—PPARG—melanoma	8.19e-07	8.06e-06	CbGpPWpGaD
Celecoxib—PTGS2—Disease—MAPK1—melanoma	8.17e-07	8.03e-06	CbGpPWpGaD
Celecoxib—PTGS2—Disease—EGFR—melanoma	8.16e-07	8.03e-06	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—PPARG—melanoma	8.12e-07	7.99e-06	CbGpPWpGaD
Celecoxib—ALB—Metabolism—PIK3CB—melanoma	7.87e-07	7.75e-06	CbGpPWpGaD
Celecoxib—ALB—Metabolism—PTGS2—melanoma	7.8e-07	7.68e-06	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—PIK3CA—melanoma	7.77e-07	7.64e-06	CbGpPWpGaD
Celecoxib—PTGS2—Disease—KRAS—melanoma	7.71e-07	7.59e-06	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—ABCB1—melanoma	7.7e-07	7.57e-06	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—TP53—melanoma	7.51e-07	7.39e-06	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—PIK3CD—melanoma	7.46e-07	7.34e-06	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—PIK3CD—melanoma	7.4e-07	7.28e-06	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—ALB—melanoma	7.36e-07	7.24e-06	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—ALB—melanoma	7.3e-07	7.18e-06	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—HRAS—melanoma	7.19e-07	7.07e-06	CbGpPWpGaD
Celecoxib—PTGS2—Disease—PIK3CA—melanoma	7.09e-07	6.97e-06	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—PRKCA—melanoma	7.08e-07	6.97e-06	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—ERCC2—melanoma	7.02e-07	6.91e-06	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—IL6—melanoma	6.88e-07	6.77e-06	CbGpPWpGaD
Celecoxib—ALB—Metabolism—PTEN—melanoma	6.8e-07	6.69e-06	CbGpPWpGaD
Celecoxib—PTGS2—Disease—HRAS—melanoma	6.56e-07	6.45e-06	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—PIK3CB—melanoma	6.5e-07	6.4e-06	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—PIK3CB—melanoma	6.45e-07	6.34e-06	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—PTGS2—melanoma	6.44e-07	6.34e-06	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—PTGS2—melanoma	6.39e-07	6.28e-06	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—AKT1—melanoma	6.34e-07	6.24e-06	CbGpPWpGaD
Celecoxib—PTGS2—Disease—IL6—melanoma	6.27e-07	6.17e-06	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—PIK3CA—melanoma	5.93e-07	5.84e-06	CbGpPWpGaD
Celecoxib—PTGS2—Disease—AKT1—melanoma	5.79e-07	5.69e-06	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—PTEN—melanoma	5.62e-07	5.53e-06	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—PTEN—melanoma	5.57e-07	5.48e-06	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—PIK3CG—melanoma	5.55e-07	5.46e-06	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—PPARG—melanoma	5.35e-07	5.27e-06	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—PIK3CD—melanoma	4.88e-07	4.8e-06	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—AKT1—melanoma	4.85e-07	4.77e-06	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—ALB—melanoma	4.81e-07	4.74e-06	CbGpPWpGaD
Celecoxib—ALB—Metabolism—PIK3CA—melanoma	4.8e-07	4.72e-06	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—PIK3CB—melanoma	4.25e-07	4.18e-06	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—PTGS2—melanoma	4.21e-07	4.14e-06	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—PIK3CA—melanoma	3.96e-07	3.9e-06	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—PIK3CA—melanoma	3.93e-07	3.87e-06	CbGpPWpGaD
Celecoxib—ALB—Metabolism—AKT1—melanoma	3.92e-07	3.86e-06	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—PTEN—melanoma	3.67e-07	3.61e-06	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—AKT1—melanoma	3.24e-07	3.19e-06	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—AKT1—melanoma	3.21e-07	3.16e-06	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—PIK3CA—melanoma	2.59e-07	2.55e-06	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—AKT1—melanoma	2.12e-07	2.08e-06	CbGpPWpGaD
